Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
267 words
Iminoquinone precursors having the formula: ##STR12## wherein (1) R 1 is hydrogen; phosphate; pyrophosphate; glycosyl; ribosyl; C 1 -C 30 acyl or arylacyl wherein said acyl or arylacyl is attached to the remainder of said formula by a --CO-- group; deoxyribosyl; aminoacyl having the formula --COCHR 5 NH 2 where R 5 is selected from the group consisting of side chains present in naturally occurring amino acids; bovine serum albumin; or sulfate; (2) R 2 and R 3 independently represent R 1 , alkyl, aryl, or arylalkyl; (3) R 4 is R 2 , halogen, cyano, a radical of the formula ##STR13## wherein (a) R 5 is selected from the group consisting of side chains present in naturally occurring amino acids and (b) R 6 represents hydroxy; alkoxy; --O - M + where M + represents a singly charged metal ion; bovine serum albumin; or ##STR14## a radical of the formula ##STR15## where R 5 and R 6 have the meanings previously defined; (4) O represents oxygen or --NH--; and (5) W, X, Y and Z independently represent hydrogen, halogen, hydroxy, alkoxy, aryloxy, alkylthio, amino, carboxyl, formyl, alkylamino, dialkylamino, acylamino, cyano, or nitro, or X and W or Y and Z taken together represents a carbocyclic ring having 5 to 6 ring atoms; (6) with the provisos that at least one of R 1 or R 2 must be an enzymatically hydrolyzable phosphate, pyrophosphate, glycosyl, ribosyl, deoxyribosyl, acyl, arylacyl, aminoacyl, bovine serum albumin, or sulfate group and when R 1 is hydrogen, neither R 3 nor R 4 may inhibit the enzymatic hydrolysis of R 2 .
Claim 2
Dependent Claim
267 words
Iminoquinone precursors having the formula: ##STR12## wherein (1) R 1 is hydrogen; phosphate; pyrophosphate; glycosyl; ribosyl; C 1 -C 30 acyl or arylacyl wherein said acyl or arylacyl is attached to the remainder of said formula by a --CO-- group; deoxyribosyl; aminoacyl having the formula --COCHR 5 NH 2 where R 5 is selected from the group consisting of side chains present in naturally occurring amino acids; bovine serum albumin; or sulfate; (2) R 2 and R 3 independently represent R 1 , alkyl, aryl, or arylalkyl; (3) R 4 is R 2 , halogen, cyano, a radical of the formula ##STR13## wherein (a) R 5 is selected from the group consisting of side chains present in naturally occurring amino acids and (b) R 6 represents hydroxy; alkoxy; --O - M + where M + represents a singly charged metal ion; bovine serum albumin; or ##STR14## a radical of the formula ##STR15## where R 5 and R 6 have the meanings previously defined; (4) O represents oxygen or --NH--; and (5) W, X, Y and Z independently represent hydrogen, halogen, hydroxy, alkoxy, aryloxy, alkylthio, amino, carboxyl, formyl, alkylamino, dialkylamino, acylamino, cyano, or nitro, or X and W or Y and Z taken together represents a carbocyclic ring having 5 to 6 ring atoms; (6) with the provisos that at least one of R 1 or R 2 must be an enzymatically hydrolyzable phosphate, pyrophosphate, glycosyl, ribosyl, deoxyribosyl, acyl, arylacyl, aminoacyl, bovine serum albumin, or sulfate group and when R 1 is hydrogen, neither R 3 nor R 4 may inhibit the enzymatic hydrolysis of R 2 .
Claim 3
Dependent Claim
32 words
The iminoquinone precursors of claim 1, wherein R 1 is hydrogen; R 2 is acyl, arylacyl, aminoacyl or phosphate; R 3 is hydrogen; and R 4 is --CHR 5 COR 6 .
Claim 4
Dependent Claim
11 words
The iminoquinone precursors of claim 2, wherein R 2 is aminoacyl.
Claim 5
Dependent Claim
29 words
The iminoquinone precursors of claim 3, wherein R 2 is ##STR16## where R 5 is selected from the group consisting of side chains present in naturally occurring amino acids.
Claim 6
Dependent Claim
31 words
The iminoquinone precursors of claim 4, wherein R 6 represents hydroxy, alkoxy having 1-5 carbon atoms, or --O - M + where M + represents a singly charged alkali metal ion.
Claim 7
Dependent Claim
11 words
The iminoquinone precursors of claim 5, wherein R 5 is hydrogen.
Claim 8
Dependent Claim
11 words
The iminoquinone precursors of claim 6, which is β-N-(L-leucyl)-α-N-(carboxymethyl ethyl ester)-p-hydroxyphenylhydrazine.
Claim 9
Dependent Claim
11 words
The iminoquinone precursors of claim 6, which is β-N-(L-phenylalanyl)-β-N-(carboxymethyl ethyl ester)-p-hydroxyphenylhydrazine.
Claim 10
Dependent Claim
11 words
The iminoquinone precursors of claim 6, which is β-N-(L-alanyl)-α-N-(carboxymethyl ethyl ester)-p-hydroxyphenylhydrazine.
Claim 11
Dependent Claim
11 words
The iminoquinone precursors of claim 6, which is β-N-(L-lysyl)-α-N-carboxymethyl ethyl ester)-p-hydroxyphenylhydrazine.
Claim 12
Dependent Claim
11 words
The iminoquinone precursors of claim 6, which is β-N-(L-glutamyl)-α-N-carboxymethyl ethyl ester)-p-hydroxyphenylhydrazine.
Claim 13
Dependent Claim
23 words
The iminoquinone precursors of claim 4, having the formula ##STR17## wherein Prot represents bovine serum albumin and t is from 1 to 500.
Claim 14
Dependent Claim
19 words
The iminoquinone precursors of claim 12, wherein Prot represent bovine serum albumin and t is from 1 to 120.
Claim 15
Dependent Claim
17 words
The iminoquinone precursors of claim 13, wherein R 5 is (CH 3 ) 2 CHCH 2 --.
Claim 16
Dependent Claim
27 words
A method of forming an iminoquinone in situ in a biological system, comprising administering a compound as described in claim 1, 2 or 4 to an organism.
Claim 17
Dependent Claim
21 words
The method of claim 15, wherein said organism is a unicellular organism or a yeast and said administering is by contact.
Claim 18
Dependent Claim
20 words
The method of claim 15, wherein said organism is a multi-cellular organism and administering is by contact, injection or ingestion.
Claim 19
Dependent Claim
30 words
The method of claim 17, wherein said iminoquinone is selectively formed in a first cell or tissue in the presence of a second cell or tissue in a multi-cellular organism.
Claim 20
Dependent Claim
17 words
The method of claim 15, wherein said administering is in the presence of a suitable pharmaceutical carrier.
Claim 21
Dependent Claim
17 words
The method of claim 17, wherein said administering is in the presence of a suitable pharmaceutical carrier.